daptomycin

Summary

Summary: A lipopeptide antibiotic that inhibits gram-positive bacteria.

Top Publications

  1. ncbi An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 54:5222-33. 2010
  2. ncbi Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus
    Nagendra N Mishra
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, 1124 West Carson St, Torrance, California 90502, USA
    Antimicrob Agents Chemother 53:2312-8. 2009
  3. ncbi Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus
    Lisa Friedman
    Cubist Pharmaceuticals, Inc, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 50:2137-45. 2006
  4. ncbi Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
    Jared A Silverman
    Cubist Pharmaceuticals, Inc, Lexington, Massachusetts 02421, USA
    Antimicrob Agents Chemother 47:2538-44. 2003
  5. ncbi Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms
    Soo Jin Yang
    Los Angeles Biomedical Research Institute, Torrance, California 90502, USA
    Antimicrob Agents Chemother 54:3079-85. 2010
  6. ncbi Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus
    Soo Jin Yang
    Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    J Infect Dis 200:1916-20. 2009
  7. ncbi Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization
    Arunachalam Muthaiyan
    Microbiology Group, Department of Biological Sciences, Illinois State University, Normal, IL 61790 4120, USA
    Antimicrob Agents Chemother 52:980-90. 2008
  8. ncbi Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan 113 8421
    Antimicrob Agents Chemother 50:1079-82. 2006
  9. ncbi Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding
    Tiffanny Jones
    Los Angeles Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, Bldg RB2, Room 225, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:269-78. 2008
  10. ncbi Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype
    Ilana Lopes Baratella da Cunha Camargo
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 52:4289-99. 2008

Research Grants

  1. Clinical Research Training in Infectious Diseases
    David Snydman; Fiscal Year: 2007
  2. Modification of daptomycin by combinatorial biosynthesis
    Paul Brian; Fiscal Year: 2005
  3. Development of furanones for treatment of anthrax
    Martin Blaser; Fiscal Year: 2005
  4. Structure activity relationships around lipopeptides
    Paul Brian; Fiscal Year: 2003
  5. Reducing Antimicrobial Use Associated with Ventilator Associated Pneumonia and Ca
    Sara Cosgrove; Fiscal Year: 2009
  6. Reducing Antimicrobial Use Associated with Ventilator Associated Pneumonia and Ca
    SARA ELIZABETH COSGROVE; Fiscal Year: 2010
  7. Genetic Basis of Virulence of Community MRSA Clone USA300
    Henry F Chambers; Fiscal Year: 2010
  8. PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    Henry Chambers; Fiscal Year: 2003
  9. FUNGAL PROTEIN/GLYCOPROTEIN EXPRESSION IN TINEA CAPITIS
    Susan Abdel Rahman; Fiscal Year: 2003
  10. Intra-species regulatory functions of fsr
    Satish Pillai; Fiscal Year: 2004

Detail Information

Publications264 found, 100 shown here

  1. ncbi An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 54:5222-33. 2010
    ..the establishment of a Staphylococcus aureus laboratory strain, 10 3d1, having reduced susceptibility to daptomycin and heterogeneous vancomycin-intermediate S. aureus (VISA) phenotype...
  2. ncbi Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus
    Nagendra N Mishra
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, 1124 West Carson St, Torrance, California 90502, USA
    Antimicrob Agents Chemother 53:2312-8. 2009
    Our previous studies of clinical daptomycin-resistant (Dap(r)) Staphylococcus aureus strains suggested that resistance is linked to the perturbations of several key cell membrane (CM) characteristics, including the CM order (fluidity), ..
  3. ncbi Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus
    Lisa Friedman
    Cubist Pharmaceuticals, Inc, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 50:2137-45. 2006
    b>Daptomycin is a lipopeptide antibiotic with potent activity against gram-positive bacteria...
  4. ncbi Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
    Jared A Silverman
    Cubist Pharmaceuticals, Inc, Lexington, Massachusetts 02421, USA
    Antimicrob Agents Chemother 47:2538-44. 2003
    The objective of this study was to further elucidate the role of membrane potential in the mechanism of action of daptomycin, a novel lipopeptide antibiotic...
  5. ncbi Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms
    Soo Jin Yang
    Los Angeles Biomedical Research Institute, Torrance, California 90502, USA
    Antimicrob Agents Chemother 54:3079-85. 2010
    The mechanism(s) of daptomycin (DAP) resistance (DAPr) is incompletely defined...
  6. ncbi Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus
    Soo Jin Yang
    Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    J Infect Dis 200:1916-20. 2009
    ..we investigated the transcriptional profiles of the mprF and dlt genes in the context of cell-surface charge and daptomycin nonsusceptibility...
  7. ncbi Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization
    Arunachalam Muthaiyan
    Microbiology Group, Department of Biological Sciences, Illinois State University, Normal, IL 61790 4120, USA
    Antimicrob Agents Chemother 52:980-90. 2008
    b>Daptomycin is a lipopeptide antibiotic that has recently been approved for treatment of gram-positive bacterial infections. The mode of action of daptomycin is not yet entirely clear...
  8. ncbi Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan 113 8421
    Antimicrob Agents Chemother 50:1079-82. 2006
    We present here findings of a strong positive correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus (VISA)...
  9. ncbi Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding
    Tiffanny Jones
    Los Angeles Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, Bldg RB2, Room 225, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:269-78. 2008
    Increasingly frequent reports have described the in vivo loss of daptomycin susceptibility in association with clinical treatment failures. The mechanism(s) of daptomycin resistance is not well understood...
  10. ncbi Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype
    Ilana Lopes Baratella da Cunha Camargo
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 52:4289-99. 2008
    In order to better understand the mechanism of daptomycin resistance, we generated a daptomycin-nonsusceptible derivative strain, strain 10*3d1 (MIC = 3...
  11. ncbi Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin
    Anne Kathrin John
    Infectious Diseases Service, Department of Internal Medicine, University Hospital and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    Antimicrob Agents Chemother 53:2719-24. 2009
    ..We compared the activity of daptomycin (alone and with rifampin [rifampicin]) with the activities of other antimicrobial regimens against MRSA ATCC ..
  12. ncbi Genetic basis for daptomycin resistance in enterococci
    Kelli L Palmer
    Departments of Ophthalmology and Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 55:3345-56. 2011
    ..The lipopeptide antibiotic daptomycin is approved to treat Gram-positive bacterial infections, including those caused by enterococci...
  13. ncbi Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia
    Peter E Pertel
    Cubist Pharmaceuticals, Lexington, Massachusetts 02421, USA
    Clin Infect Dis 46:1142-51. 2008
    We sought to compare daptomycin with ceftriaxone for the treatment of patients with community-acquired pneumonia (CAP).
  14. ncbi Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:3162-5. 2009
    Vancomycin and daptomycin MIC results for 1,800 randomly selected oxacillin (methicillin [meticillin])-resistant Staphylococcus aureus (MRSA) bloodstream isolates from nine U.S...
  15. ncbi Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations
    Molly E Steed
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA
    Antimicrob Agents Chemother 54:5187-92. 2010
    Reduced susceptibility to daptomycin has been reported in patients with infections due to methicillin-resistant Staphylococcus aureus (MRSA)...
  16. ncbi Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus
    Esteban Nannini
    Division of Infectious Diseases, School of Medicine, Universidad Nacional de Rosario, Rosario, Argentina
    Curr Opin Pharmacol 10:516-21. 2010
    ..Nonsusceptibility to daptomycin has been associated with changes in the structure and function of the cell envelope and surface charge...
  17. ncbi Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations
    Warren E Rose
    Department of Pharmacy Practice, Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit Receiving Hospital, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 52:3061-7. 2008
    ..We evaluated the impact of simulated standard- and high-dose daptomycin in combination with gentamicin or rifampin against daptomycin-susceptible and nonsusceptible matched strains of ..
  18. ncbi Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
    O Murillo
    Laboratory of Experimental Infection, Infectious Diseases Service, IDIBELL, Hospital Universitari de Bellvitge, Feixa Llarga s n, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Antimicrob Agents Chemother 53:4252-7. 2009
    Since the currently approved dose of daptomycin (6 mg/kg of body weight/day) has been associated with clinical failures and resistance development, higher doses for some difficult-to-treat infections are being proposed...
  19. ncbi Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
    C Garrigós
    Infectious Diseases Service, Hospital Universitari de Bellvitge, Feixa Llarga s n, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Antimicrob Agents Chemother 54:5251-6. 2010
    ..The aim of this study was to evaluate the efficacies of daptomycin at usual and high doses (equivalent to 6 and 10 mg/kg of body weight/day, respectively, in humans) and in ..
  20. ncbi Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")
    Soo Jin Yang
    LA Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, RB 2, Rm 230, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 54:3161-9. 2010
    In vivo development of daptomycin resistance (DAPr) among Staphylococcus aureus strains, especially methicillin-resistant S. aureus (MRSA) strains, in conjunction with clinical treatment failures, has emerged as a major problem...
  21. ncbi Genetic basis for in vivo daptomycin resistance in enterococci
    Cesar A Arias
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX 77030, USA
    N Engl J Med 365:892-900. 2011
    b>Daptomycin is a lipopeptide with bactericidal activity that acts on the cell membrane of enterococci and is often used off-label to treat patients infected with vancomycin-resistant enterococci...
  22. ncbi Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy
    Fred C Tenover
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30333, USA
    Int J Antimicrob Agents 33:564-8. 2009
    ..aureus (MRSA) bacteraemia developed endocarditis, failed a second course of vancomycin and then failed daptomycin therapy...
  23. ncbi In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates
    Louis Saravolatz
    St John Hospital and Medical Center, 19251 Mack Ave, Suite 333, Detroit, MI 48236, USA
    Antimicrob Agents Chemother 54:3027-30. 2010
    ..aureus (VISA), vancomycin-resistant S. aureus (VRSA), heteroresistant VISA (hVISA), and daptomycin-nonsusceptible S. aureus (DNSSA) isolates...
  24. ncbi Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis
    M Lefebvre
    Universite de Nantes, Faculte de Medecine, EA3826, 1 rue Gaston Veil, F 44035 Nantes, France
    Int J Antimicrob Agents 36:542-4. 2010
    b>Daptomycin exhibits rapid bactericidal activity against Gram-positive organisms, including meticillin-resistant Staphylococcus aureus (MRSA). Daptomycin in combination with rifampicin needs to be assessed in bone infection...
  25. ncbi Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis
    Mark S Rouse
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Antimicrob Chemother 57:301-5. 2006
    ..b>Daptomycin is a cyclic lipopeptide anti-infective with activity against MRSA, approved for treatment of complicated skin ..
  26. ncbi Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 65:158-62. 2009
    ..to 2008 in hospitals located in the United States were tested by reference broth microdilution methods against daptomycin and comparison agents. Methicillin (oxacillin) resistance rates were 55.9% and 74...
  27. ncbi Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years
    Maria D Appleman
    Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Diagn Microbiol Infect Dis 66:441-4. 2010
    We investigated vancomycin and daptomycin efficacy for Staphylococcus aureus isolates at our institution by testing 221 methicillin-sensitive and 299 methicillin-resistant isolates recovered from serious infections between 1979 and 2007 ..
  28. ncbi Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study
    Jan T Kielstein
    Department of Nephrology and Hypertension, Medical School Hannover, Germany
    Nephrol Dial Transplant 25:1537-41. 2010
    b>Daptomycin is a new intravenous cyclic lipopeptide antibiotic, licensed for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms including both susceptible and resistant strains of Staphylococcus ..
  29. ncbi Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model
    Molly Steed
    Anti Infective Research Laboratory, School of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 55:3522-6. 2011
    ..potential role of ceftaroline, a new broad-spectrum cephalosporin, as a therapeutic option for the treatment of daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) infections...
  30. ncbi Daptomycin: a review 4 years after first approval
    Robert Sauermann
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
    Pharmacology 81:79-91. 2008
    b>Daptomycin is the first approved member of a new class of antibiotics, namely the cyclic lipopeptides. Daptomycin has rapid bactericidal activity against Gram-positive pathogens...
  31. ncbi Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis
    Kathleen Julian
    Penn State Milton S Hershey Medical Center, Room C6833, BMR Bldg, Mailcode H036, 500 University Dr, Hershey, PA 17033, USA
    Antimicrob Agents Chemother 51:3445-8. 2007
    We analyzed the emergence of daptomycin nonsusceptibility in a patient with persistent vancomycin-intermediate Staphylococcus aureus (VISA) bacteremia...
  32. ncbi Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians
    Theodoros Kelesidis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
    Clin Infect Dis 52:228-34. 2011
    b>Daptomycin is the only antibiotic with in vitro bactericidal activity against vancomycin-resistant Enterococcus (VRE) that is approved by the Food and Drug Administration (FDA)...
  33. ncbi The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion
    Christoph M Ernst
    Cellular and Molecular Microbiology Division, Interfaculty Institute of Microbiology and Infection Medicine, University of Tubingen, Tubingen, Germany
    PLoS Pathog 5:e1000660. 2009
    ..a crucial role in Staphylococcus aureus virulence and it is involved in resistance to the CAMP-like antibiotic daptomycin. MprF is a large membrane protein that modifies the anionic phospholipid phosphatidylglycerol with l-lysine, ..
  34. ncbi Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy
    Pamela A Moise
    Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA
    Ann Pharmacother 43:1211-9. 2009
    b>Daptomycin is approved for the treatment of skin and skin-structure infections (4 mg/kg) and Staphylococcus aureus bacteremia, including right-sided endocarditis (6 mg/kg)...
  35. ncbi Daptomycin in experimental murine pneumococcal meningitis
    Barry B Mook-Kanamori
    Division of Infectious Disease, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
    BMC Infect Dis 9:50. 2009
    b>Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for treatment of pneumococcal meningitis...
  36. ncbi A potential role for daptomycin in enterococcal infections: what is the evidence?
    Rafael Canton
    Servicio de Microbiologia, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain
    J Antimicrob Chemother 65:1126-36. 2010
    ..b>Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections...
  37. ncbi Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program
    D A Figueroa
    Department of Pharmacy, New York Hospital Queens, Flushing, New York 11355, USA
    Clin Infect Dis 49:177-80. 2009
    There are limited safety data for high-dose and long-term daptomycin treatment (16mg/kg administered for >or=14 days). We present our experience in 61 patients.
  38. ncbi Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate
    Madhukiran H Murthy
    Department of Internal Medicine and Infectious Disease, University of Nebraska Medical Center, Omaha, USA
    J Med Microbiol 57:1036-8. 2008
    b>Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant Staphylococcus aureus (MRSA)...
  39. ncbi Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:4127-32. 2009
    ..We evaluated the possible occurrence of MIC creep when testing vancomycin and daptomycin against methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) by using precise incremental reference ..
  40. ncbi Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE)
    John F Mohr
    Cubist Pharmaceuticals, Inc, 65 Hayden Avenue, Lexington, MA 02421, USA
    Int J Antimicrob Agents 33:543-8. 2009
    ..Studies in vitro as well as animal and case studies suggest that daptomycin may be effective in enterococcal infections...
  41. ncbi Daptomycin: mechanisms of action and resistance, and biosynthetic engineering
    Richard H Baltz
    Discovery Biology, Cubist Pharmaceuticals, Inc, 65 Hayden Avenue, Lexington, MA 02421, USA
    Curr Opin Chem Biol 13:144-51. 2009
    b>Daptomycin is a lipopeptide antibiotic used clinically to treat infections caused by Gram-positive bacteria. Laboratory studies have shown that Staphylococcus aureus resistance to daptomycin occurs stepwise and slowly...
  42. ncbi Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic
    Sara E Cosgrove
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 48:713-21. 2009
    ..This study evaluated the association between this practice and nephrotoxicity...
  43. ncbi The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
    Robert D Arbeit
    Cubist Pharmaceuticals, Lexington, Massachusetts 02421, USA
    Clin Infect Dis 38:1673-81. 2004
    b>Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and ..
  44. ncbi Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
    Vance G Fowler
    Duke University Medical Center, Durham, NC 27710, USA
    N Engl J Med 355:653-65. 2006
    ..Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed...
  45. ncbi Clinical experience with daptomycin for the treatment of patients with osteomyelitis
    Kenneth C Lamp
    Cubist Pharmaceuticals, Inc, Lexington, Massachusetts, USA
    Am J Med 120:S13-20. 2007
    Data from a registry were analyzed to describe the clinical experience with daptomycin (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA) for the treatment of patients with osteomyelitis...
  46. ncbi Resistance studies with daptomycin
    J A Silverman
    Cubist Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    Antimicrob Agents Chemother 45:1799-802. 2001
    We studied the in vitro emergence of resistance to daptomycin using three methods: spontaneous resistance incidence, serial passage in the presence of increasing drug concentrations, and chemical mutagenesis...
  47. ncbi Intermediate vancomycin susceptibility in a community-associated MRSA clone
    Christopher J Graber
    Division of Infectious Diseases, University of California, San Francisco General Hospital, 94110, USA
    Emerg Infect Dis 13:491-3. 2007
    ..Staphylococcus aureus (MRSA) with intermediate susceptibility to vancomycin and reduced susceptibility to daptomycin. The strain was isolated from the bone of a 56-year-old man with lumbar osteomyelitis after a 6-week treatment ..
  48. ncbi Mechanisms of resistance to daptomycin in Enterococcus faecium
    Clemente I Montero
    Microbiology Service, Department of Laboratory Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, US Department of Health and Human Services, 10 Center Drive, MSC 1508, Bethesda, Maryland 20892 1508, USA
    Antimicrob Agents Chemother 52:1167-70. 2008
    In this study, we investigated the clonal emergence of daptomycin-resistant Enterococcus faecium strains isolated from a patient with leukocyte adhesion deficiency syndrome...
  49. ncbi Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus
    Joanne Karen Hobbs
    Antimicrobial Research Centre and Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK
    J Antimicrob Chemother 62:1003-8. 2008
    The proposed lethal action of daptomycin on Staphylococcus aureus results from the loss of K(+) and membrane depolarization. However, whether these events alone cause cell death has been questioned...
  50. ncbi Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF
    Satish K Pillai
    Department of Infectious Disease, Cleveland Clinic Foundation, Mailstop S32, Cleveland, OH 44195, USA
    Antimicrob Agents Chemother 51:2223-5. 2007
    A previous study documented the presence of mutations in mprF that accompanied the loss of daptomycin susceptibility among Staphylococcus aureus isolates following exposure to the drug...
  51. ncbi Daptomycin for the treatment of surgical site infections
    Ronald S Chamberlain
    Department of Surgery, St Barnabas Medical Center, Livingston, NJ 07039, USA
    Surgery 146:316-24. 2009
    ..The increasing frequency of methicillin-resistant Staphylococcus aureus (MRSA) as a cause of surgical site infections, and decreased susceptibility to vancomycin, highlight the need for alternative therapies...
  52. ncbi Daptomycin in bone and joint infections: a review of the literature
    Dennis A K Rice
    St Joseph s Candler Health System, Savannah, GA, USA
    Arch Orthop Trauma Surg 129:1495-504. 2009
    To review the pharmacology, pharmacokinetics, efficacy, and safety of daptomycin, a novel antibiotic for the treatment of bone and joint infections, a literature search of relevant articles was conducted.
  53. ncbi Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus
    Pierre Vaudaux
    Division of Infectious Diseases, Geneva University Hospital, CH 1211 Geneva 14, Switzerland
    J Antimicrob Chemother 52:89-95. 2003
    The therapeutic activity of daptomycin was compared with that of vancomycin in a rat model of subcutaneously implanted tissue cages chronically infected with strain Rev1, a spontaneous methicillin-susceptible revertant of the methicillin-..
  54. ncbi Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo
    Elizabeth C Weiss
    Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Antimicrob Agents Chemother 53:4096-102. 2009
    ..sarA) has an impact on the susceptibility of established Staphylococcus aureus biofilms to treatment with daptomycin in vivo...
  55. ncbi Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies
    Judith N Steenbergen
    Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA
    J Antimicrob Chemother 64:1130-8. 2009
    This review summarizes the in vitro and animal model data available on antibiotic combinations with daptomycin. The majority of studies focus on the clinically relevant combinations of daptomycin with rifampicin or with gentamicin...
  56. ncbi Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria
    Lawrence I Mortin
    Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 51:1787-94. 2007
    The rising rates of antibiotic resistance accentuate the critical need for new antibiotics. Daptomycin is a new antibiotic with a unique mode of action and a rapid in vitro bactericidal effect against gram-positive organisms...
  57. ncbi Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm
    Philip S Stewart
    Center for Biofilm Engineering, Department of Chemical and Biological Engineering, Montana State University, Bozeman, MT 59717 3980, USA
    Antimicrob Agents Chemother 53:3505-7. 2009
    Fluorescently tagged daptomycin accessed the interior of Staphylococcus epidermidis biofilm cell clusters within minutes. The diffusion coefficient of daptomycin in the biofilm was 28% of its value in pure water...
  58. ncbi Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus
    Brian Quinn
    Public Health Research Institute and Department of Microbiology and Molecular Genetics, UMDNJ New Jersey Medical School, 225 Warren Street, Newark, NJ 07103, USA
    J Antimicrob Chemother 60:1380-3. 2007
    ..Large bacterial inocula known to reduce susceptibility have not been studied for effects on MPC determination...
  59. ncbi Daptomycin in the treatment of patients with infective endocarditis: experience from a registry
    Donald P Levine
    Wayne State University, University Health Center, Detroit, Michigan, USA
    Am J Med 120:S28-33. 2007
    b>Daptomycin (Cubicin; Cubist Pharmaceuticals, Inc...
  60. ncbi Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy
    James S Lewis
    Antimicrob Agents Chemother 49:1664-5. 2005
  61. ncbi Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection
    A Louie
    Division of Infectious Diseases, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 45:845-51. 2001
    b>Daptomycin is a lipopeptide antibiotic with activity against gram-positive bacteria, including Staphylococcus aureus. We defined the pharmacodynamic parameters that determine the activity of daptomycin for S...
  62. ncbi Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation
    Ute Bertsche
    Interfacultary Institute of Microbiology and Infection Medicine, Microbial Genetics, University of Tubingen, Auf der Morgenstelle 28, 72076 Tubingen, Germany
    Antimicrob Agents Chemother 55:3922-8. 2011
    Cell wall thickening is a common feature among daptomycin-resistant Staphylococcus aureus strains. However, the mechanism(s) leading to this phenotype is unknown...
  63. ncbi Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis
    Anna Barbara Hachmann
    Department of Microbiology, Wing Hall, Cornell University, Ithaca, NY 14853 8101, USA
    Antimicrob Agents Chemother 55:4326-37. 2011
    b>Daptomycin (DAP) is a cyclic lipopeptide that disrupts the functional integrity of the cell membranes of Gram-positive bacteria in a Ca(2+)-dependent manner...
  64. ncbi Lipid-specific binding of the calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of model membranes
    David Jung
    Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada
    Chem Phys Lipids 154:120-8. 2008
    b>Daptomycin is a cyclic anionic lipopeptide with an antibiotic activity that is completely dependent on the presence of calcium (as Ca2+). In a previous study [Jung et al., 2004. Chem. Biol...
  65. ncbi Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis
    Denis Grandgirard
    Laboratory for Experimental Neuroinfectiology, Institute for Infectious Diseases, University of Bern, Bern, Switzerland
    Antimicrob Agents Chemother 54:1323-6. 2010
    ..inflammation were assessed in an infant rat pneumococcal meningitis model for the nonbacteriolytic antibiotic daptomycin versus ceftriaxone...
  66. ncbi Daptomycin as a possible new treatment option for surgical management of Methicillin-Resistant Staphylococcus aureus sternal wound infection after cardiac surgery
    Aron F Popov
    Department of Thoracic and Cardiovascular Surgery, University of Gottingen, Germany
    J Cardiothorac Surg 5:57. 2010
    ..with an aortic valve replacement and developed three month later a Methicillin-Resistant Staphylococcus aureus (MRSA) sternal wound infection which was successful treated with Daptomycin combined with vacuum-assisted closure (VAC).
  67. ncbi Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study
    David J Farrell
    Quotient Bioresearch Limited, Newmarket Road, Fordham, Cambs CB75WW, United Kingdom
    Antimicrob Agents Chemother 55:1177-81. 2011
    ..Further investigations using S. aureus NRS384 (USA300) and daptomycin demonstrated a 64-fold increase in the MIC after 55 passages (from 0...
  68. ncbi Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus
    Aileen Rubio
    Cubist Pharmceuticals, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 55:364-7. 2011
    Mutations in mprF have been shown to result in reduced susceptibility to daptomycin and other cationic antibacterials...
  69. ncbi Effects of tigecycline and daptomycin on murine gut colonization by Candida albicans
    George Samonis
    Division of Medicine, University of Crete, Crete, Greece
    Mycoses 51:324-7. 2008
    ..Both groups were subsequently given tigecycline or daptomycin or normal saline subcutaneously for 10 days...
  70. ncbi Daptomycin structure and mechanism of action revealed
    Jason Micklefield
    Department of Chemistry, University of Manchester Institute of Science and Technology, PO Box 88, Manchester M60 1QD, United Kingdom
    Chem Biol 11:887-8. 2004
    b>Daptomycin kills otherwise antibiotic-resistant gram-positive pathogens and is the first lipopeptide antibiotic to reach the clinic...
  71. ncbi Clinical outcomes with daptomycin: a post-marketing, real-world evaluation
    G Sakoulas
    Division of Infectious Diseases, New York Medical College, Valhalla, New York, NY, USA
    Clin Microbiol Infect 15:11-6. 2009
    The Cubicin Outcomes Registry and Experience (CORE) is an ongoing, retrospective, post-marketing database of daptomycin use in the USA...
  72. ncbi Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis
    Yasir Lal
    Sanford School of Medicine of the University of South Dakota, Sioux Falls, 57105, USA
    Clin Infect Dis 50:737-40. 2010
    We present 2 elderly patients who developed lung infiltrates associated with eosinophilia during intravenous daptomycin treatment. Both patients improved quickly after daptomycin was stopped and steroid treatment was initiated...
  73. ncbi Organizing pneumonia and pulmonary eosinophilic infiltration associated with daptomycin
    Elizabeth Cobb
    Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
    Ann Pharmacother 41:696-701. 2007
    To report a case of organizing pneumonia with pulmonary eosinophilic infiltrates in a patient receiving daptomycin.
  74. ncbi Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin
    Anna Barbara Hachmann
    Department of Microbiology, Wing Hall, Cornell University, Ithaca, New York 14853 8101, USA
    Antimicrob Agents Chemother 53:1598-609. 2009
    b>Daptomycin is the first of a new class of cyclic lipopeptide antibiotics used against multidrug-resistant, gram-positive pathogens...
  75. ncbi Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry
    Kenneth V I Rolston
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 8:249-56, 90. 2010
    Clinical data for daptomycin in the treatment of neutropenic cancer patients with documented gram-positive infections are limited...
  76. ncbi Are glycopeptides still appropriate and convenient for empiric use?
    A Gonzalez-Ruiz
    Darent Valley Hospital, Kent, UK
    J Chemother 20:531-41. 2008
    ..We report the cost savings of a formulary decision to replace teicoplanin with daptomycin for the empiric treatment of complicated skin and soft tissue infections (CSSTIs), staphylococcal bacteraemia ..
  77. ncbi Daptomycin: a new drug class for the treatment of Gram-positive infections
    Jeffrey D Alder
    Cubist Pharmaceuticals, Lexington, Massachusetts 02421, USA
    Drugs Today (Barc) 41:81-90. 2005
    b>Daptomycin is the first member of a new class of bactericidal antibiotics, the cyclic lipopeptides...
  78. ncbi Daptomycin in the treatment of bacteremia
    George Sakoulas
    New York Medical College, Valhalla, New York, USA
    Am J Med 120:S21-7. 2007
    The aim of this study was to describe the clinical experience with daptomycin in the treatment of bacteremia...
  79. ncbi Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains
    Soo Jin Yang
    LA Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, RB 2, Rm 230, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 53:2636-7. 2009
    ..strains to study (i) regulation of mprF-mediated phosphatidylglycerol lysinylation in the contexts of in vitro daptomycin (DAP) nonsuceptibility and (ii) the role of mprF mutation in endovascular virulence...
  80. ncbi Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials
    Glenn A Pankuch
    Department of Pathology, Hershey Medical Center, PO Box 850, Hershey, PA 17033, USA
    J Antimicrob Chemother 51:443-6. 2003
    ..macrolides and quinolones was tested for susceptibility to nine antibiotics, including the novel lipopeptide daptomycin. Daptomycin was active against all strains (MIC range </=0.5 mg/L; MIC(50) 0.125 mg/L; MIC(90) 0.25 mg/L)...
  81. ncbi Daptomycin: pharmacology and clinical use
    Christos Kosmidis
    Wayne State University, Department of Medicine, University Health Center, Suite 5C, 4201 St Antoine, Detroit, MI 48201, USA
    Expert Opin Pharmacother 11:615-25. 2010
    Infections caused by Gram-positive organisms have increased in frequency and severity. Daptomycin offers a therapeutic option in an era of increasing resistance.
  82. ncbi Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
    Daniel J Skiest
    Baystate Medical Center, Division of Infectious Diseases, 759 Chestnut St, Springfield, MA 01199, USA
    J Clin Microbiol 44:655-6. 2006
    b>Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA)...
  83. ncbi Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection
    Abhijit Chakraborty
    Novartis Institutes for BioMedical Research, East Hanover, NJ, USA
    J Antimicrob Chemother 64:151-8. 2009
    ..separate populations of healthy adult volunteers investigated the pharmacokinetics, safety and tolerability of daptomycin (Cubicin; Novartis Pharma AG, Basel, Switzerland) administered as a 2 min intravenous (iv) injection, relative ..
  84. ncbi Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
    Peter G Kelley
    Department of Microbiology, Austin Health, Heidelberg, Victoria, Australia
    J Antimicrob Chemother 66:1057-60. 2011
    The aim of this study was to establish the relationship between reduced vancomycin and daptomycin susceptibility among Australasian vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA) isolates from patients ..
  85. ncbi Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL
    M Torrico
    Microbiology Department, School of Medicine, Universidad Complutense, Avda Complutense s n, 28040 Madrid, Spain
    Int J Antimicrob Agents 35:131-7. 2010
    ..the influence of vancomycin tolerance and protein binding on the bactericidal activity of vancomycin versus daptomycin (protein binding 36.9% vs. 91...
  86. ncbi Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure
    Susan Boyle-Vavra
    Department of Pediatrics, University of Chicago, KCBD 4152, 900 E 57th Street, Chicago, IL 60657, USA
    Antimicrob Agents Chemother 55:2018-25. 2011
    We describe here a clinical daptomycin treatment failure in a patient with recurrent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in whom daptomycin was administered after a failed empirical treatment course with ..
  87. ncbi Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature
    S J van Hal
    Department of Microbiology and Infectious Diseases, Sydney South West Pathology Service Liverpool, Sydney, New South Wales, Australia
    Eur J Clin Microbiol Infect Dis 30:603-10. 2011
    A patient developed a daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) infection, despite being daptomycin-naïve, in the setting of persistent bacteraemia secondary to vertebral osteomyelitis...
  88. ncbi Eosinophilic pneumonia induced by daptomycin
    Don Hayes
    Department of Pediatrics, University of Kentucky College of Medicine, J410 Kentucky Clinic, Lexington, KY 40536, USA
    J Infect 54:e211-3. 2007
    We present a case of drug-induced eosinophilic pneumonia resulting from intravenous daptomycin being used as therapy for recurrent methicillin-sensitive Staphlococcus aureus endocarditis...
  89. ncbi Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006
    Robert L Holmes
    Infectious Disease Service, Brooke Army Medical Center, Fort San Houston, Texas 78234, USA
    Antimicrob Agents Chemother 52:757-60. 2008
    We assessed MICs and minimal bactericidal concentrations of vancomycin, daptomycin, and nine other antimicrobials against methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006...
  90. ncbi Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations
    J Brauers
    Antiinfectives Intelligence GmbH, Von Liebig Strasse 20, 53359 Rheinbach, Germany
    Int J Antimicrob Agents 29:322-5. 2007
    The bactericidal activities of daptomycin, vancomycin, teicoplanin and linezolid at human peak free serum concentrations (C(max,free)) were determined against Staphylococcus aureus (one methicillin-susceptible and two methicillin-..
  91. ncbi Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis
    S Lemaire
    Unité de Pharmacologie Cellulaire et Moléculaire, Universite Catholique de Louvain, Bruxelles, Belgium
    Clin Microbiol Infect 14:766-77. 2008
    ..Four isogenic isolates (three from tissue, one from blood) with increased MICs for vancomycin (1-4 mg/L) and for daptomycin (1-4 mg/L) were collected after an initial 16-day treatment with vancomycin-rifampicin-gentamicin, followed by ..
  92. ncbi Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model
    Prachi K Dandekar
    Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    J Antimicrob Chemother 52:405-11. 2003
    OBJECTIVE: To describe the pharmacodynamic profile of daptomycin against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci species based on bacterial density in an immunocompromised mouse thigh infection model...
  93. ncbi Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus
    Jason W Bennett
    Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Diagn Microbiol Infect Dis 60:437-40. 2008
    ..Staphylococcus aureus (MRSA) bacteremia was treated sequentially with vancomycin plus rifampin then daptomycin plus gentamicin...
  94. ncbi In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium
    Laura A Jevitt
    Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
    Microb Drug Resist 9:389-93. 2003
    We assessed the in vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin (QD) against a contemporary challenge panel of 88 staphylococcal and 90 enterococcal isolates...
  95. ncbi Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations
    Raymond Cha
    Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, School of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 47:3960-3. 2003
    ..model with simulated endocardial vegetations incorporating protein and a high inoculum was used to simulate daptomycin, linezolid, quinupristin-dalfopristin, and vancomycin against the Michigan VRSA strain...
  96. ncbi Optimizing therapy for methicillin-resistant Staphylococcus aureus bacteremia
    Sara E Cosgrove
    Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, 600 N Wolfe Street, Baltimore, MD 21287, USA
    Semin Respir Crit Care Med 28:624-31. 2007
    ..aureus endocarditis is life threatening. Selection of an appropriate antibiotic regimen is also an essential factor for optimal management...
  97. ncbi Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model
    Raymond Cha
    Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
    J Antimicrob Chemother 54:259-62. 2004
    OBJECTIVE: Daptomycin exhibits bactericidal activity against clinically significant Gram-positive bacteria despite being highly bound to human proteins...
  98. ncbi Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vi
    Kerry L LaPlante
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 52:2156-62. 2008
    ..45 to 1.3 logs). Overall, administration of daptomycin followed by vancomycin demonstrated the most significant kill against all strains in both models...
  99. ncbi Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus
    Francesc Marco
    Microbiology Service, Hospital Clinic, Institut d Investigacions Biomèdiques August Pi Sunyer, University of Barcelona School of Medicine, Barcelona, Catalunya, Spain
    Antimicrob Agents Chemother 52:2538-43. 2008
    b>Daptomycin is a lipopeptide antibiotic with potent in vitro activity against gram-positive cocci, including Staphylococcus aureus...
  100. ncbi Beyond MRSA: the growing menace of hVISA and VISA
    Deepti Bulchandani
    South Med J 101:663-4. 2008
  101. ncbi Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections
    Cindy A Loffler
    University of California, San Francisco Medical Center, 521 Parnassus Ave, C 152, San Francisco, CA 94122, USA
    Expert Rev Anti Infect Ther 5:961-81. 2007
    ..Newer agents, such as linezolid and daptomycin, are aiming to improve on the poor cure rates found with vancomycin in serious MRSA infections, but definitive ..

Research Grants28

  1. Clinical Research Training in Infectious Diseases
    David Snydman; Fiscal Year: 2007
    ..The goal of this training program will be to develop independent infectious diseases clinical research investigators highly skilled in clinical research methodologies and application. ..
  2. Modification of daptomycin by combinatorial biosynthesis
    Paul Brian; Fiscal Year: 2005
    The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and ..
  3. Development of furanones for treatment of anthrax
    Martin Blaser; Fiscal Year: 2005
    ..Ciprofloxacin or daptomycin will be used as comparitors, and synergies with the furanones explored as well...
  4. Structure activity relationships around lipopeptides
    Paul Brian; Fiscal Year: 2003
    ..The most notable lipopeptide from the 10-membered ring group is daptomycin that is currently progressing through clinical trials...
  5. Reducing Antimicrobial Use Associated with Ventilator Associated Pneumonia and Ca
    Sara Cosgrove; Fiscal Year: 2009
    ..We hypothesize that this approach will enhance appropriate use of antimicrobials for both VAP and CAUTI and improve patient outcomes by reducing the known sequelae of antimicrobial overuse. ..
  6. Reducing Antimicrobial Use Associated with Ventilator Associated Pneumonia and Ca
    SARA ELIZABETH COSGROVE; Fiscal Year: 2010
    ..We hypothesize that this approach will enhance appropriate use of antimicrobials for both VAP and CAUTI and improve patient outcomes by reducing the known sequelae of antimicrobial overuse. ..
  7. Genetic Basis of Virulence of Community MRSA Clone USA300
    Henry F Chambers; Fiscal Year: 2010
    ..By knocking each of these genes out and testing for loss of virulence, we hope to learn which genes code for virulence. Once these genes are identified, strategies to block their effects may be developed. ..
  8. PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    Henry Chambers; Fiscal Year: 2003
    ..To augment information about where PBPs localize, when they are expressed during the cell cycle will be determined by Northern blotting. ..
  9. FUNGAL PROTEIN/GLYCOPROTEIN EXPRESSION IN TINEA CAPITIS
    Susan Abdel Rahman; Fiscal Year: 2003
    ..abstract_text> ..
  10. Intra-species regulatory functions of fsr
    Satish Pillai; Fiscal Year: 2004
    ..abstract_text> ..
  11. Evaluating Trichophyton tonsurans Carriage and Infection
    Susan Abdel Rahman; Fiscal Year: 2006
    ..abstract_text> ..
  12. Mentored Patient-Oriented Research Careeer Development Award
    Debra Poutsiaka; Fiscal Year: 2007
    ..abstract_text> ..
  13. Genetic Analysis of HIV Complications
    Alexandra Mangili; Fiscal Year: 2007
    ....
  14. B-lactam mediated SOS response and expression of resistance in clinical MRSA
    Adriana E Rosato; Fiscal Year: 2010
    ....